Make sure you get the green bottle

Image of a climber swinging from a mouth of a cave

FREQUENTLY ASKED
QUESTIONS (FAQs)

What is glaucoma?

Glaucoma is a disease that damages the eye’s optic nerve, often caused by extra fluid that increases pressure in the eye.

Open-angle glaucoma is the most common form of glaucoma. It develops gradually and often goes unnoticed at first. Regular eye exams are important to find early signs of damage to the optic nerve.

Is there a cure for glaucoma?

While there is no cure for glaucoma, studies show that lowering high eye pressure can help reduce the risk of glaucoma-related vision loss. That's why daily treatment of high eye pressure is very important. Remember, high eye pressure can slowly, but permanently, damage your optic nerve before you notice any change in vision.

What can I do to manage my glaucoma or high eye pressure?

Your doctor can recommend a prescription eye drop to help you manage your glaucoma or high eye pressure. One option is ALPHAGAN® P 0.1%.

What is ALPHAGAN® P 0.1%?

ALPHAGAN® P 0.1% ophthalmic solution is an FDA-approved eye medication used to lower high eye pressure in patients with open-angle glaucoma or ocular hypertension (high eye pressure). There is no FDA-approved generic version of ALPHAGAN® P 0.1%. If your doctor prescribes ALPHAGAN® P 0.1%, check to make sure you receive the correct medication when you pick it up.

Why did my doctor choose ALPHAGAN® P 0.1%?

Prescription eye drops are commonly used to reduce high eye pressure. ALPHAGAN® P 0.1% is a FDA-approved medication proven to lower high eye pressure in patients with open-angle glaucoma or ocular hypertension (high eye pressure).

How do I use ALPHAGAN® P 0.1%?

The recommended dose of ALPHAGAN® P 0.1% is 1 drop in the affected eye(s) 3 times a day, about 8 hours apart. If you use more than 1 type of topical eye drop, just be sure to apply them at least 5 minutes apart.

If you have open-angle glaucoma or ocular hypertension (high eye pressure), it is important to continue your ALPHAGAN® P 0.1% therapy. Don’t skip or stop treatment (unless you have spoken to your doctor). Remembering to use your eye drops is easier if you make it part of your daily routine.

If you wear contact lenses, remove them first, then wait 15 minutes after using ALPHAGAN® P 0.1% before you put them back into your eyes.

What are the most common side effects of ALPHAGAN® P 0.1%?

In a 3-month long study, the most common side effects of ALPHAGAN® P 0.1% were eye allergies (allergic conjunctivitis), eye redness (hyperemia), and itchy eyes (eye pruritus). If you develop these or other side effects, contact your eye doctor immediately. 10% to 20% of patients (n=215) experienced allergic conjunctivitis, conjunctival hyperemia, and eye pruritus. 5% to 9% of patients (n=215) experienced burning sensation, conjunctival folliculosis, hypertension, ocular allergic reaction, oral dryness, and visual disturbance.

How can I save on my ALPHAGAN® P 0.1% prescription?

Eligible customers can qualify to pay as little as $15 FOR 90 days of medication.* To access savings on your ALPHAGAN® P 0.1% prescription, enroll online here. You can also enroll for discounts by calling 1-833-Dial-AYS (1-833-342-5297), or texting SAVINGS to 72428.


*Offer not valid for patients enrolled in Medicare, Medicaid, a Medicare drug benefit plan, TRICARE, or other federal or state health programs (such as medical assistance programs). Other limitations may apply. This offer is valid for up to 12 prescription fills for a 30-day supply and 4 prescription fills for a 90-day supply per medication. Offer applies only to prescriptions filled before the program expires on 05/01/20. This offer cannot be combined with any other programs, offers, or discounts, and may not be redeemed for cash. Allergan reserves the right to rescind, revoke, or amend this offer without notice at any time.

INDICATIONS AND USAGE

ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% or 0.15% is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Neonates and Infants (under the age of 2 years): ALPHAGAN® P is contraindicated in neonates and infants (under the age of 2 years).

Hypersensitivity Reactions: ALPHAGAN® P is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past.

WARNINGS AND PRECAUTIONS

Potentiation of Vascular Insufficiency: ALPHAGAN® P may potentiate syndromes associated with vascular insufficiency. ALPHAGAN® P should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans.

Severe Cardiovascular Disease: Although brimonidine tartrate ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease.

Contamination of Topical Ophthalmic Products After Use: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.

DRUG INTERACTIONS

Antihypertensives/Cardiac Glycosides: Because ALPHAGAN® P may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with ALPHAGAN® P is advised.

CNS Depressants: Although specific drug interaction studies have not been conducted with ALPHAGAN® P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.

Tricyclic Antidepressants: Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. It is not known whether the concurrent use of these agents with ALPHAGAN® P in humans can lead to resulting interference with the IOP-lowering effect. Caution is advised in patients taking tricyclic antidepressants, which can affect the metabolism and uptake of circulating amines.

Monoamine Oxidase Inhibitors: Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side effect such as hypotension. Caution is advised in patients taking MAO inhibitors, which can affect the metabolism and uptake of circulating amines.

ADVERSE REACTIONS

Adverse reactions occurring in approximately 10% to 20% of the subjects receiving brimonidine ophthalmic solution (0.1% to 0.2%) included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritus. Adverse reactions occurring in approximately 5% to 9% included: burning sensation, conjunctival folliculosis, hypertension, ocular allergic reaction, oral dryness, and visual disturbance

Please click here for full ALPHAGAN® P 0.1% Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1 (800)-FDA-1088.